通过瘤特异性,补充激活抗体促进抗瘤免疫程序
Ruchi Saxena1, Ryan T Bushey2, Michael J Campa2
1Department of Integrative Immunobiology, Duke University School of Medicine, Durham, NC.
Journal of immunology (Baltimore, Md. : 1950)
|April 1, 2024
概括
像GT103这样的瘤向抗体可以启动抗瘤免疫力. 这种抗体针对癌细胞的补充因子H (CFH),增强免疫反应并抑制瘤生长.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 瘤向抗体对于启动抗瘤免疫反应和在癌症患者中实现持久的临床反应至关重要.
- 对补充因子H (CFH) 的自身抗体与早期非小细胞肺癌有关.
- 从患者B细胞中克隆的mAb,GT103,能够识别瘤特异性的CFH表位,并表现出体外和体内瘤抗瘤活性.
研究的目的:
- 阐明针对瘤表位的抗体促进有效的抗瘤免疫反应的机制.
- 在临床前模型中,研究一种鼠化版本的GT103 (mGT103) 对瘤微环境和抗瘤免疫力的影响.
- 探索GT103作为治疗剂的潜力,与其他免疫疗法结合使用.
主要方法:
- 利用合成的CMT167肺瘤C57BL/6小鼠模型来研究mGT103的影响.
- 分析了mGT103.3介导的补充和增强抗瘤免疫力的激活.
- 评估了瘤微环境的变化,包括调节性T细胞和骨髓系衍生抑制细胞.
- 评估了mGT103与抗PD-L1 mAb结合的添加剂抗瘤作用.
- 检查了表达抗CFH自身抗体的早期患者瘤的免疫景观.
主要成果:
- 化GT103 (mGT103) 通过多种途径激活补充剂并增强抗瘤免疫力.
- mGT103通过减少免疫抑制调节性T细胞和骨髓系衍生抑制细胞,创造了有利的瘤微环境.
- mGT103增强了抗原特异效应T细胞,并与抗PD-L1 mAb结合时表现出添加性抗瘤作用.
- 患有抗CFH自身抗体的早期患者的瘤显示出免疫活性瘤微环境.
- GT103针对瘤细胞上存在的独特CFH表位.
结论:
- GT103,一种针对瘤特异性CFH表位体的抗体,激活补充物并产生免疫程序以抑制瘤生长.
- 这项研究提供了关于瘤特异性补充激活抗体如何引起有效的抗瘤免疫反应的新机制性见解.
- 这些发现支持GT103在癌症治疗中的治疗潜力,特别是在组合策略中.
相关概念视频
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cytotoxic T Cells-mediated Immune Response
907
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
907
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cell-mediated Immune Responses
68.2K
Overview
68.2K


